• We know how to improve serology testing performance

    Solutions for the precise detection of SARS-CoV-2 antibody natural response and immunity after vaccination. 

  • SARS-CoV-2 Multiantigen IgG + IgA + IgM Assay

    COVID-19  Multiplex Bead-Based Immunoassay simultaneously targeting four separate SARS-Cov-2 specific antigens and 3 immunoglobulins.

  • Anti-SARS-Cov-2 ELISA Spike IgG Kits

    Designed to monitor SARS-CoV-2 immune response, detecting antibodies generated as a response to SARS-CoV-2 natural infection and vaccination.

  • SARS-CoV-2 Serology Testing by Flow Cytometry

    Watch our webinar again

  • SARS-COV-2 ELISA Mpro IgG Kits

    Highly sensitive and accurate test screening patients whose immune system has reacted to the virus as a result of natural infection.

  • Developed and Manufactured in Spain

    Guaranteed Supply. Patented under Spanish National Research Council (CSIC) licence.

Innovating to deliver
high-quality reliable serology testing technology.

At IMMUNOSTEP we  develop innovative solutions in order to help improve research and diagnostic performance in key areas of development.

We will continue to work every day to deliver high-quality technology in order to fight against the global health emergency by assuring reliable results.

Our Commitment:
Reliability and Innovation

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a virus that belongs to the family of coronaviruses, of the genus Betacoronavirus, which emerged in China in the city of Wuhan, Hubei province, in December 2019 and it has spread throughout the world until being declared by WHO as a pandemic in March 2020.

In response to the Covid-19 pandemic, CSIC research groups have worked in collaboration with Immunostep to develop these serological tests capable of detecting specific SARS-CoV-2 antibodies  and monitoring immune responses with an estimated accuracy close to 100%.

Reliability

Detecting SARS-CoV-2 immune response with an  accuracy close to 100%.

INNOVATION

High sensitivity and specifity targeting highly antigenic structural and  non-structural proteins.

EFFICIENCY

Very early antibody detection from the symptoms onset identifying IgG, IgA and IgM immunoglobulins.

Research and Development

We work everyday to improve serology testing performance by innovating and adapting new technology to collaborate building meaningful clinical investigation. 

 

DO YOU STILL HAVE ANY DOUBT

ABOUT OUR INNOVATIVE COVID-19 TESTS?

CE/IVD kits are only suitable for clinical use in European Union and countries with EU conformity recognition agreements. Manufactured in Spain by Immunostep under CSIC Patent License.